Abstract
Background: Remodeling spacing factor 1 (RSF-1/HBXAP) has been linked to a variety of cancer types, however, its roles and the therapeutic potential are not clear in cervical cancer.Methods: RSF-1 expression in cancer tissues was analyzed by immunohistochemical staining followed by statistical analysis with SPSS. Anti-RSF-1 studies were performed by treating cells with specific siRNA or a dominant mutant form (RSF-D4).Results: RSF-1 expression correlates with cancer progression that strongly-positive staining can be found in 67.7% carcinomas and 66.7% CIN lesions, but none in normal tissues. Such overexpression also associated with increased tumor size, poor differentiation, higher nodal metastasis and advanced clinical stages. Kaplan– Meier analysis confirmed that cancer patients with high RSF-1 levels exhibited a significantly shorter survival time than those with low RSF-1 levels. Downregulation of RSF-1 by siRNA silencing or RSF-D4 reduced cell growth and increased drug sensitivity toward paclitaxel treatment in HeLa cells.Conclusions: RSF-1 participates in the tumor progression of cervical cancer and could be considered as an early prognostic marker for cancer development and clinical outcome. Therapies based on anti-RSF-1 activity may be beneficial for patients with RSF-1 overexpression in their tumors.
Highlights
Cervical cancer is one of the most common gynecological malignancies and the fourth prevalent cause of cancer-related death in women [1]
Tumor histology analysis indicated that 30.0 % of total cancer patients were diagnosed as adenocarcinomas and 70.0 % of them were squamous carcinomas
As compared to normal and cervical intraepithelial neoplasia (CIN) tissues, RSF-1 protein was significantly upregulated in malignant cervical carcinomas, as shown in Fig. 1B (p = 0.0005)
Summary
Cervical cancer is one of the most common gynecological malignancies and the fourth prevalent cause of cancer-related death in women [1]. Several relatively effective therapies, such as platinum-based chemo drugs and concurrent chemoradiotherapy (CCRT), are available for treating patients, locoregional recurrence-free survival (LRFS), diseasefree survival (DFS) and overall survival (OS) are still low and need to be improved Due to such limitations, it is necessary to identify other molecular effectors that influence oncogenesis of cervical cancer in order to find more effective and safe strategies or therapeutic avenues for preventing and curing cervical cancer. Results: RSF-1 expression correlates with cancer progression that strongly-positive staining can be found in 67.7% carcinomas and 66.7% CIN lesions, but none in normal tissues Such overexpression associated with increased tumor size, poor differentiation, higher nodal metastasis and advanced clinical stages. Therapies based on anti-RSF-1 activity may be beneficial for patients with RSF-1 overexpression in their tumors
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
